Bio Pharma Dive

MARCH 14, 2023

Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75%.

Insulin 280

Insulin Drugs Branding Medicine 280

Bio Pharma Dive

FEBRUARY 8, 2023

In a State of the Union address, Biden threatened to veto any efforts to repeal the legislation and chastised drugmakers for the current costs of insulin.

Insulin 139

Insulin Drugs 139

Medical Xpress

MARCH 17, 2023

French pharmaceutical giant Sanofi announced on Thursday it would cut the US price of its most prescribed insulin by 78 percent, falling in line with two other major drug makers.

Insulin 95

Insulin Drugs 95

pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Pharmacy 105

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Insulin 130

Insulin Marketing Sales Compliance 130

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. cases of hypoglycaemia per year with insulin icodec, versus 0.27 events for the once-daily drug. In absolute terms, there were 0.73

Insulin 98

Insulin Trials Drugs Production 98

pharmaphorum

JULY 29, 2021

Generic drugmaker Mylan has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi’s once-daily insulin Lantus.

Insulin 98

Insulin Drugs Production Generic Drugs 98

STAT News

JANUARY 20, 2023

In an attempt to tackle the root causes of inflated insulin prices, the state of California filed a lawsuit last week accusing drug manufacturers and pharmacy benefit managers of artificially and illegally jacking up the price of insulin. The sausage-making of how insulin is priced is not for the faint of heart.

Insulin 105

Insulin Pharmacy Manufacturing Drugs 105

Drug Discovery World

FEBRUARY 19, 2024

Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). Following this, blood glucose levels in the diabetic NHP began to fluctuate and increase markedly, and insulin injections needed to be resumed.

Insulin 52

Insulin Immune Response Engineer Antibody 52

Bio Pharma Dive

NOVEMBER 18, 2022

Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

FDA Approval 273

FDA Approval Insulin Drugs 273

Drug Channels

SEPTEMBER 15, 2023

Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products. d/b/a Drug Channels Institute.

Insulin 71

Insulin Manufacturing Drugs Production 71

Medical Xpress

FEBRUARY 16, 2023

Two classes of drugs prescribed off-label for some patients with type 1 diabetes can provide significant benefits, but also come with health concerns, according to a study by UT Southwestern Medical Center researchers.

Insulin 98

Insulin Drugs Research 98

BioPharma Reporter

JANUARY 29, 2024

Synthetic biology company rBIO has completed all required analytical characterizations of its insulin biosimilar, R-biolin.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

Medical Xpress

NOVEMBER 15, 2022

In a new 'Ideas and Opinions,' authors from Johns Hopkins Bloomberg School of Public Health analyze California's newly announced effort to manufacture insulin for its residents. The commentary is published in Annals of Internal Medicine.

Insulin 98

Insulin Manufacturing Medicine Drugs 98

Bio Pharma Dive

MARCH 22, 2023

The companies will collaborate to identify compounds that could treat insulin resistance by targeting shape-shifting cellular droplets known as biomolecular condensates.

Insulin 287

Insulin Drugs 287

XTalks

OCTOBER 8, 2021

Medtronic has expanded a Class I recall of remote controllers used with the MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps over potential cybersecurity risks. The medtech giant has also expanded another Class I recall of the retainer rings on its 600 series insulin pumps.

Insulin 128

Insulin Life Science Drugs Regulation 128

NPR Health - Shots

MARCH 1, 2023

The moves announced Wednesday promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin they need in order to live. Image credit: Darron Cummings/AP)

Insulin 105

Insulin Drugs 105

Medical Xpress

APRIL 11, 2023

An international study shows that it is likely that insulin can be stored at room temperature, and for considerably longer than drug companies have counted on to date. Access to this vital medicine can thereby be significantly improved for the world's poorest inhabitants.

Insulin 98

Insulin Scientist Medicine Drugs 98

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 281

Gene Editing Insulin Gene Licensing 281

BioPharma Reporter

NOVEMBER 21, 2022

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 98

Insulin Drug Delivery Development Drugs 98

NPR Health - Shots

SEPTEMBER 12, 2022

Drug price reforms passed as part of the Inflation Reduction Act did not solve the problem of skyrocketing costs of insulin. States are taking their own action.

Insulin 118

Insulin Drugs 118

STAT News

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments. The company plans to cut the list price of its NovoLog insulin by 75%, and the prices for Novolin and Levemir by 65% starting in January 2024.

Insulin 98

Insulin Branding Production Drugs 98

XTalks

MARCH 15, 2024

LillyDirect Pharmacy Solutions, Eli Lilly’s direct-to-consumer (DTC) drugs website, is teaming up with Amazon Pharmacy to deliver select medications to people’s homes. The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab).

Pharmacy 111

Pharmacy Drugs Insulin Branding 111

STAT News

MARCH 3, 2023

… Now that Eli Lilly slashed the price for some of its insulin products, the moves raised questions about what will happen to other efforts to provide low-cost insulin, Kaiser Health News explains. And the Mark Cuban Cost Plus Drug Co. plans to sell low-cost insulin. And the Mark Cuban Cost Plus Drug Co.

Insulin 98

Insulin Drugs Production Marketing 98

STAT News

DECEMBER 15, 2022

In a bid to widen access to insulin in primarily low-income nations in Africa, Eli Lilly has agreed to sell active pharmaceutical ingredients and transfer technology to an Egyptian company that expects to supply the life-saving diabetes treatment to as many as 1 million people by 2030.

Insulin 115

Insulin Manufacturing Drugs 115

STAT News

MARCH 9, 2023

Now that Eli Lilly is cutting prices on some of its insulin products, Sen. This week, he introduced a bill that would place a $20 cap on all insulin, a move designed to drastically lower costs for millions of Americans. Bernie Sanders (I-Vt.) is seeking to build on that momentum. Continue to STAT+ to read the full story…

Insulin 98

Insulin Manufacturing Production Drugs 98

Bio Pharma Dive

SEPTEMBER 14, 2023

New weight loss drugs have sparked a stock selloff for some device makers, but medtech analysts don’t see them a likely to undermine the companies’ business — yet.

Insulin 148

Insulin Drugs 148

pharmaphorum

JULY 14, 2021

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. . It was also responsible for the first recombinant insulin product – Humulin – which launched in 1982 and remains on sale.

Insulin 98

Insulin Protein Production Sales 98

XTalks

JULY 14, 2023

The US Food and Drug Administration (FDA) has granted clearance to Tandem Diabetes Care, Inc.’s s Tandem Mobi insulin pump for individuals six years of age and older with diabetes. Tandem has dubbed The Mobi to be the world’s smallest insulin pump. Users can also self-administer bolus insulin doses manually.

Insulin 52

Insulin Regulation Marketing Drugs 52

STAT News

MARCH 2, 2023

What happens when a drug company actually lowers prices? We also discuss the latest news in the life sciences, including Eli Lilly slashing the cost of insulin, succession at the FDA, and how pandemic boom times have turned to bust. Who invented CRISPR 2.0? And is Novavax going to survive? Read the rest…

Insulin 98

Insulin Life Science Drugs 98

NPR Health - Shots

MARCH 18, 2023

More drug companies lowered list prices for insulin this week. NPR's Scott Simon speaks with Kaiser Health News reporter Bram Sable-Smith about what that means for patients.

Insulin 57

Insulin Drugs 57

Bio Pharma Dive

AUGUST 16, 2023

The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

Insulin 130

Insulin Pharmacy Manufacturing Drugs 130

Drug Channels

JANUARY 9, 2024

For 2024, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again each excluded 600 or more drugs from their standard formularies. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Insulin 88

Insulin Pharmacy Drugs Production 88

BioPharma Reporter

MAY 3, 2023

Protein drugs are notoriously difficult to deliver orally â but scientists have developed a new type of oral capsule that could deliver insulin and other similar drugs.

Insulin 52

Insulin Scientist Development Protein 52

pharmaphorum

JANUARY 12, 2023

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 59

Insulin Trials Development Drugs 59

Medical Xpress

MARCH 21, 2023

A recent UNC-Chapel Hill School of Medicine study has concluded that metformin—a drug used to control high blood sugar—along with insulin did not reduce risks for adverse neonatal outcomes compared with a placebo along with insulin in pregnancies with type 2 diabetes.

Insulin 72

Insulin Medicine Drugs 72

STAT News

MARCH 16, 2023

Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The change comes after Eli Lilly and then Novo Nordisk announced plans this month to reduce list prices for some of their own insulin products by similar amounts. The moves will go into effect on Jan.

Insulin 98

Insulin Manufacturing Production Marketing 98